Exelixis is a high-quality biotechnology business with a return on equity of approximately 41%, margins the data characterizes as strong at roughly 35%, and four consecutive quarters of approximately 16% positive earnings surprises — but the stock's price has reached and marginally exceeded the analyst consensus target, leaving no meaningful upside buffer and creating an unfavorable entry point at current levels.
Thesis pillars
- Exceptional Financial Quality→Stable
- Single Product Concentration Risk↑Improving
- Price At Target No Asymmetry→Stable
- +1 more pillar — see the Why tab for full reasoning
Exelixis, Inc. (EXEL) Stock Analysis
Range Bound setup
Healthcare · Biotechnology
Wait for pullback to $46.11. Recent C-suite change — blocks BUY_NOW at $54.08. Engine's entry $46.11 (Default 5pct Sticky) is the shallowest technical level that clears the 2:1 A.R:R minimum. Key risks: Concentration risk — Product: cabozantinib; Analyst target reached - limited upside remaining.
Exelixis commercializes CABOMETYX and COMETRIQ (both cabozantinib formulations) for multiple cancer indications in the U.S., generating $2,122.8 million in net product revenues in 2025 plus $179.2 million in royalties from partners Ipsen and Takeda for ex-U.S. markets.... Read more
Wait for pullback to $46.11. Recent C-suite change — blocks BUY_NOW at $54.08. Engine's entry $46.11 (Default 5pct Sticky) is the shallowest technical level that clears the 2:1 A.R:R minimum. Key risks: Concentration risk — Product: cabozantinib; Analyst target reached - limited upside remaining. Chart setup: RSI 47 mid-range, Bollinger mid-band. Wide-moat business. Accumulate on weakness. Score 6.4/10, moderate confidence.
Passes 6/8 gates (positive momentum, clean insider activity, news events none recent, earnings proximity 66d clear, semi cycle peak clear, materials cycle peak clear). Fails on favorable risk/reward ratio. Suitability: speculative.
About Exelixis, Inc.
About Exelixis, Inc.
CABOMETYX — approved for advanced RCC (April 2016 as monotherapy, January 2021 in combination with nivolumab), previously treated HCC (January 2019), DTC (September 2021), and pNET/epNET (March 2025) — generated $2,122.8 million in Exelixis net product revenues in 2025, up from $1,809.4 million in 2024. Collaboration partners Ipsen (outside U.S. and Japan) and Takeda (Japan) paid $179.2 million in royalties on ex-U.S. cabozantinib sales in 2025. CABOMETYX holds approvals in 68 countries outside the U.S.
Exelixis earns product revenue from direct U.S. sales of CABOMETYX tablets and COMETRIQ capsules to oncology patients, with pricing dependent on commercial payers, Medicare, and Medicaid. The company implemented a 340B Program Integrity Initiative in 2022, limiting contract pharmacy designations to one per covered entity and requiring claims-level data; three administrative dispute resolution petitions from covered entities allege overcharges, and multiple states have enacted laws requiring broader contract pharmacy access, creating ongoing litigation and regulatory uncertainty. Outside the U.S., Exelixis earns royalties on net sales by Ipsen and Takeda without bearing promotional costs in those markets. The March 2025 pNET/epNET FDA approval — based on the Alliance-led CABINET Phase 3 trial — broadens the addressable market to an estimated 161,000 to 192,000 patients with advanced NET. Zanzalintinib, the lead pipeline asset with an FDA review underway for certain forms of colorectal cancer, is also in late-stage trials for RCC, NET, and meningioma.
Show full overview
The Inflation Reduction Act poses a pricing transition risk. Exelixis has qualified for the small biotech exception protecting cabozantinib from Medicare drug price negotiation through Initial Price Applicability Year 2027 and reapplied for IPAY 2028, but that protection is time-limited and drug-specific. CMS announced the next 15 drugs selected for negotiation on January 27, 2026, with resulting maximum fair prices taking effect in 2028. A May 12, 2025 executive order directing HHS to pursue most-favored-nation price targets — with proposed rulemaking if manufacturers do not voluntarily comply — may further constrain revenues from CABOMETYX if implemented.
See also: Healthcare · Biotechnology
From Exelixis, Inc.'s most recent 10-K filing, extracted June 10, 2026.
Recent developments
updated 2026-08-22Recent Developments — Exelixis, Inc.
Latest news
- NEWS EXEL|Exelixis Inc|Price:55.505|Chg%:+0.175 - TradingKey — TradingKey neutral
- NEWS EXEL|Exelixis Inc|Price:55.505|Chg%:+0.175 - tradingkey.com — tradingkey.com neutral
- NEWS EXEL|Exelixis Inc|Price:55.487|Chg%:+0.158 - TradingKey — TradingKey neutral
- NEWS EXEL|Exelixis Inc|Price:56.520|Chg%:+0.710 - TradingKey — TradingKey neutral
- NEWS EXEL|Exelixis Inc|Price:56.520|Chg%:+0.710 - tradingkey.com — tradingkey.com neutral
Generated 2026-08-23T00:51:55Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHProductcabozantinib10-K Item 1: 'Sales related to cabozantinib account for the majority of our revenues'
Material Events(8-K, last 90d)
- 2026-05-29Item 5.02LOWStockholders approved the amendment and restatement of the 2017 Equity Incentive Plan at the May 26, 2026 Annual Meeting, effective immediately upon approval. Routine compensatory plan amendment; no officer departure or appointment.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
1 ceiling hit
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Wait for pullback to $46.11. Recent C-suite change — blocks BUY_NOW at $54.08. Engine's entry $46.11 (Default 5pct Sticky) is the shallowest technical level that clears the 2:1 A.R:R minimum. Key risks: Concentration risk — Product: cabozantinib; Analyst target reached - limited upside remaining. Chart setup: RSI 47 mid-range, Bollinger mid-band. Wide-moat business. Accumulate on weakness. Target $55.81 (+3.2%), stop $42.57 (−27.0%), A.R:R -1.6:1. Score 6.4/10, moderate confidence.
Take-profit target: $55.81 (-11.8% upside). Target $55.81 (+3.2%), stop $42.57 (−27.0%), A.R:R -1.6:1. Stop-loss: $42.57.
Concentration risk — Product: cabozantinib; Analyst target reached - limited upside remaining.
Exelixis, Inc. trades at a P/E of 16.9 (forward 13.0). TrendMatrix value score: 6.8/10. Verdict: Buy (Wait for Entry).
26 analysts cover EXEL with a consensus score of 3.7/5. Average price target: $53.
What does Exelixis, Inc. do?Exelixis commercializes CABOMETYX and COMETRIQ (both cabozantinib formulations) for multiple cancer indications in the...
Exelixis commercializes CABOMETYX and COMETRIQ (both cabozantinib formulations) for multiple cancer indications in the U.S., generating $2,122.8 million in net product revenues in 2025 plus $179.2 million in royalties from partners Ipsen and Takeda for ex-U.S. markets. Cabozantinib accounts for the majority of revenues; zanzalintinib is the lead pipeline asset under FDA review for colorectal cancer at the filing date.